The Bioscience and Biotechnology Sector Developments in Cancer Therapy

NEW YORK, September 26, 2016 /PRNewswire/ --

The bioscience technology sector continues to evolve, being a dynamic field which employs life processes to practical uses, such as new bioscience procedures and advanced drugs in treating viral diseases. The large and emerging volume of industry research indicates future growth within the sector. Companies from across the field have been investing in cancer research, trying to reinvent cancer therapy. Spotlight Innovation Inc. (OTCMKTS: STLT), Immune Pharmaceuticals Inc (NASDAQ: IMNP), NewLink Genetics Corp. (NASDAQ: NLNK), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Agenus Inc. (NASDAQ: AGEN)

Recently, bioscience company Spotlight Innovation Inc. (OTC: STLT) has entered into a sponsored research agreement with Florida State University to battle against the Zika virus; a virus transmitted by Aedes mosquitos that currently has no cure or specific treatment. Spotlight will be supporting FSU professor, Hengli Tang to create harmless yet effective medicine to treat patients who are infected with the virus. The company's innovation focuses on identifying and acquiring rights to proprietary technologies in areas of unmet medical need, highlighting on rare or emerging diseases and conditions such as Zika.

Spotlight Innovation Inc. (STLT) classifies and acquires rights to innovative, proprietary technologies intended to address unmet medical needs and focuses importantly on unique, emerging and neglected diseases. In order to find and assess extraordinary opportunities, the company strictly leverages their extensive relationships with well-known scientists, top academic institutions and other leading sources. This April Spotlight Innovation achieves key laboratory benchmark for Its Immunoplex™ Immunotherapy Cancer Vaccine Technology.

Spotlight Innovation Inc. (STLT) earlier in the month announced that, Cassandra K. MacArthur has joined the company as Senior Vice President of Regulatory Affairs and Compliance. Ms. MacArthur will be responsible for all aspects of regulatory affairs including strategic planning for regulatory approvals, preparation of regulatory submissions, serving as the primary contact with the FDA and other regulatory authorities, and compliance with all regulatory agencies worldwide.

NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing immuno-oncology products to improve the lives of patients suffering from cancer. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system and a clinically advanced product candidate for patients with pancreatic cancer, the Algenpantucel-L.

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. The company's technology platform, NanomAbs, is a platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) has reported positive sales last quarter of the company's first commercial product, ONIVYDE, a drug that treats patients with metastatic pancreatic cancer. The company specified sales increased by 29% compared to its first quarter, making it at $12.9 million. Merrimack aims to reduce the uncertainty in drug development and clinical validation, and move discovery efforts past trial and error. This approach could make individualized treatment of patients a reality.

Agenus Inc. (NASDAQ: AGEN) has completed enrollment of the first cohort of patients in its Phase 1 study an anti-CTLA-4 antibody (AGEN1884), which was launched earlier in this year. Agenus also plans to initiate clinical studies for a second anti-CTLA-4 antibody, the AGEN2041, in 2017 and thus combine trials with AGEN1884 during its first half of next year. Agenus is an immuno-oncology company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines.

For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated twelve thousand dollars for financial news pr services by a non-affiliated third party for spotlight innovations inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting the high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: Danny A, [email protected] , +1-877-601-1879

SOURCE FinancialBuzz.com